CAAS
TECH icon

Capital Asset Advisory Services’s Bio-Techne TECH Stock Holding History

Capital Asset Advisory Services’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,188
Closed -$94K – 1420
2020
Q4 		$94K Buy
+1,188
New +$86K 0.02% 474

Other funds holding TECH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Capital Asset Advisory Services's TECH Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of Bio-Techne (TECH) in Q1 2021, closing a stake of 1,188 shares — an estimated $94K sold.

Capital Asset Advisory Services first reported a position in TECH in Q4 2020 and held it in 1 quarter. The position peaked at $94K in Q4 2020. 470 funds tracked by Wall St. Rank hold TECH as of Q1 2021.

  • Capital Asset Advisory Services reported no remaining Bio-Techne position as of Q1 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 1,188 Bio-Techne shares in Q1 2021, an estimated $94K.
  • Capital Asset Advisory Services first reported a position in Bio-Techne in Q4 2020 and held it in 1 quarter.
  • Capital Asset Advisory Services's Bio-Techne position peaked at $94K in Q4 2020.
  • 470 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.